Study Identifies "Ideal" AIDS Drug Regimen; Includes Same Drug Types Found in Indian Generic FDCs, Study Author Says
May 4, 2004
The "ideal" antiretroviral drug combination for new patients includes two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor, according to a study in the April 29 issue of the New England Journal of Medicine, the New York Times reports. This drug combination -- known colloquially as "two nukes plus a non-nuke" -- has been produced in fixed-dose combination pill form since 2001 by Indian generic drug companies and is the same combination of drug classes that the World Health Organization has recommended since 2002 for use in developing countries, according to the Times (McNeil, New York Times, 5/4). Dr. Roy Gulick, director of the HIV clinical trials unit at Weill Cornell Medical College in New York, and colleagues tested the effectiveness of three antiretroviral drug regimens in the initial treatment of 1,147 HIV-positive people. The regimens included a triple-nucleoside treatment containing zidovudine, lamivudine and abacavir; a regimen containing the nucleosides zidovudine and lamivudine and the non-nucleoside efavirenz; and a regimen containing the triple-nucleoside combination plus efavirenz (Gulick et al., New England Journal of Medicine, 4/29). The researchers selected the drugs in an attempt to find an ideal drug regimen that avoided the use of protease inhibitors, which are effective but can cause liver damage and shifts in body fat that can cause malformations, according to the Times. Patients on the triple-nucleoside combination did so poorly that they were taken off the regimen before the study was completed, the Times reports.
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
North Carolina Health Officials Believe Syphilis Eradication Possible if Decreasing Incidence Trends Persist
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.